PT - JOURNAL ARTICLE AU - Copeland, Harriet AU - Low, Karen J AU - Wynn, Sarah AU - Ahmed, Ayesha AU - Arthur, Victoria AU - Balasubramanian, Meena AU - Bennett, Katya AU - Berg, Jonathan AU - Bertoli, Marta AU - Bryson, Lisa AU - Bucknall, Catrin AU - Campbell, Jamie AU - Chandler, Kate AU - Chauhan, Jaynee AU - Clarkson, Amy AU - Coles, Rachel AU - Conti, Hector AU - Costello, Philandra AU - Coupar, Tessa AU - Craig, Amy AU - Dean, John AU - Dillon, Amy AU - Dixit, Abhijit AU - Drew, Kathryn AU - Eason, Jacqueline AU - Forzano, Francesca AU - Foulds, Nicky AU - Gardham, Alice AU - Ghali, Neeti AU - Green, Andrew AU - Hanna, William AU - Harrison, Rachel AU - Hegarty, Mairead AU - Higgs, Jenny AU - Holder, Muriel AU - Irving, Rachel AU - Jain, Vani AU - Johnson, Katie AU - Jolley, Rachel AU - Jones, Wendy AU - Jones, Gabriela AU - Joss, Shelagh AU - Kalinauskiene, Ruta AU - Kanini, Farah AU - Kavanagh, Karl AU - Khan, Mahmudur AU - Khan, Naz AU - Kivuva, Emma AU - Lahiri, Nayana AU - Lakhani, Neeta AU - Lampe, Anne AU - Lynch, Sally Ann AU - Mansour, Sahar AU - Marsden, Alice AU - Massey, Hannah AU - McKee, Shane AU - Mohammed, Shehla AU - Naik, Swati AU - Nesarajah, Mithushanaa AU - Newbury-Ecob, Ruth AU - Osborne, Fiona AU - Parker, Michael J AU - Patterson, Jenny AU - Pottinger, Caroline AU - Prapa, Matina AU - Prescott, Katrina AU - Quinn, Shauna AU - Radley, Jessica A AU - Robart, Sarah AU - Ross, Alison AU - Rosti, Giulia AU - Sansbury, Francis AU - Sarkar, Ajoy AU - Searle, Claire AU - Shannon, Nora AU - Shears, Debbie AU - Smithson, Sarah AU - Stewart, Helen AU - Suri, Mohnish AU - Tadros, Shereen AU - Theobald, Rachel AU - Thomas, Rhian AU - Tsoulaki, Olga AU - Vasudevan, Pradeep AU - Verdesoto, Maribel AU - Vittery, Emma AU - Whyte, Sinead AU - Woods, Emily AU - Wright, Thomas AU - Zocche, David AU - Firth, Helen V AU - Wright, Caroline F AU - the DDD Study TI - Large-scale evaluation of outcomes following a genetic diagnosis in children with severe developmental disorders AID - 10.1101/2023.10.18.23297202 DP - 2023 Jan 01 TA - medRxiv PG - 2023.10.18.23297202 4099 - http://medrxiv.org/content/early/2023/10/19/2023.10.18.23297202.short 4100 - http://medrxiv.org/content/early/2023/10/19/2023.10.18.23297202.full AB - Objective We sought to evaluate outcomes for clinical management following a genetic diagnosis from the Deciphering Developmental Disorders (DDD) Study.Design Individuals in the DDD study who had a pathogenic/likely pathogenic genotype in the DECIPHER database were selected for inclusion (n=5010). Clinical notes from regional clinical genetics services notes were reviewed to assess pre-defined clinical outcomes relating to interventions, prenatal choices, and information provision.Results Outcomes were recorded for 4237 diagnosed probands (85% of those eligible) from all 24 recruiting centres across the UK and Ireland. Additional diagnostic or screening tests were performed in 903 (21%) probands through referral to a range of different clinical specialties, and stopped or avoided in a further 26 (0.6%). Disease-specific treatment was started in 85 (2%) probands, including seizure-control medications and dietary supplements, and contra-indicated medications were stopped/avoided as no longer necessary in a further 20 (0.5%).The option of prenatal/preimplantation genetic testing was discussed with 1204 (28%) families, despite the relatively advanced age of the parents at the time of diagnosis.Importantly, condition-specific information or literature was given to 3214 (76%) families, and 880 (21%) were involved in family support groups. In the most common condition (KBG syndrome; 79 (2%) probands), clinical interventions only partially reflected the temporal development of phenotypes, highlighting the importance of consensus management guidelines and patient support groups.Conclusions Our results underscore the importance of achieving a clinico-molecular diagnosis to ensure timely onward referral of patients, enabling appropriate care and anticipatory surveillance, and for accessing relevant patient support groups.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe DDD study presents independent research commissioned by the Health Innovation Challenge Fund [grant number HICF-1009-003], a parallel funding partnership between the Wellcome Trust and the Department of Health, and the Wellcome Sanger Institute [grant number WT098051]. DECIPHER is funded by Wellcome [WT223718/Z/21/Z].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The DDD study has UK Research Ethics Committee approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland REC).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://www.deciphergenomics.org/